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Purpose: Apolipoprotein M (apoM) is a plasma lipoprotein that mainly associates with high-density
lipoproteins (HDL) and that serves as a carrier of the bioactive lipid Sphingosine-1-Phosphate (S1P).
Recent studies indicate that S1P binding to G-protein-coupled receptors, known as S1P-receptors,
in the heart activates signalling pathways promoting cardiomyocyte survival, but downstream targets
are largely unknown. Here, we investigate the putative role of the apoM-S1P axis in relation to cardi-
oprotection against ischemia/reperfusion (IR) injury.
Methods and Results: ApoM transgenic (Apom-Tg) mice, in which plasma S1P is increased by
.250%, and wild-type (WT) mice were subjected to 30 min of left coronary artery ligation and 24
hrs reperfusion in vivo.We found a reduction of infarct size in Apom-Tgmice (15+1%) in comparison
withWTmice (29+4%, N=8-9, p,0.01). In agreement, neutrophil infiltration into the infarcted area
was lower in Apom-Tg mice (14.8+0.2% vs. 25.9+5.1 in WT, N=3, p,0.05). Interestingly, 5 min of
S1P treatment at the onset of reperfusion reduced infarct size in response to 30 min of no-flow global
ischemia (control: 23+3%, S1P-treated: 11+2%, N=5, p,0.05) in ex vivo Langendorff perfused
hearts, suggesting that S1P exerts a direct protective effect on cardiomyocytes. Moreover, the sensitiv-
ity to ex vivo IR of Apom-Tg mice was not different fromWTmice, further supporting that the cardi-
oprotective effect observed in vivo is due to increased plasmatic S1P in these mice. To obtain further
insight into the mechanism underlying S1P-induced cardioprotection, neonatal rat ventricular cardio-
myocytes were treated for 5min with S1P after pre-incubation with PKC kinase inhibitors orwith spe-
cific antagonists of S1P receptors.We found byWestern blot that S1P induced phosphorylation of the
gap junction protein Connexin43 (Cx43) on Serine 368 by a PKC-dependent mechanism and that this
phosphorylationwasmediated by S1P2 and S1P3 but not by S1P1 receptors. Finally, 5min of S1P treat-
ment reduced gap junctional communication between cardiomyocytes (9+1 cells, N=29) in compari-
son to control conditions (15+2 cells, N=34, p,0.01), as assessed by dye coupling assay.
Conclusion: Increased plasma apoM-S1P in mice protects the heart against IR injury. The molecular
mechanism might involve reduced cardiomyocyte death by activation of S1P2 and S1P3 receptors,
which leads to PKC-dependent phosphorylation of Cx43 and reduction of cell-to-cell coupling.
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